Over DKK 3 billion (USD 413 million) raised by BioInnovation Institute portfolio companies to date
Summary
The initial fundraise was one of the largest Series A financing rounds for a Danish biotech company.Adcendo was incubated at the BII in 2019 by being accepted into the Venture House program. Throughout the 18 months of incubation at BII, the team further refined the technology, tested the efficacy and safety of several promising candidates, strengthened the business plan and clinical strategy. Adcendo also established new partnerships and appointed an Advisory Board.As outlined in the BII Impact Report 2022, there have been a number of other success stories to note from the past year. Additionally, Synklino, a biotech start-up developing pioneering drugs for the treatment of chronic viral infections, raised EUR 29.8 million in a Series A investment.Jens Nielsen, Chief Executive Officer, at BioInnovation Institute, said: "At BII, our mission is to recognise and support early-stage life science start-ups and projects and catalyze their commercialization by using our knowledge, network, funding, and infrastructure. Adcendo is a fantastic example of success and I believe that together we can drive the development of new solutions and ultimately, positively impact the societal challenges in human and planetary health around the world.